43 articles with Deinove
DEINOVE to present data on DNV3837 at the ESCMID/ASM conference in Dublin
DEINOVE announces that a poster titled « DNV3837, a parenteral GI tract-targeted treatment for Clostridioides difficile infection » is to be presented at the ESCMID/ASM conference taking place in Dublin, from October 4 to 7.
DEINOVE presents its financial results and the advancement of its programs for 2021
DEINOVE announces that its Board of Directors has approved the consolidated financial statements for the year 2021.
Pfizer's Clostridioides difficile infection vaccine failed to hit the mark, BMS announced priority review for Opdivo in resectable Non-Small Cell Lung Cancer, and Saol enlists help from GeneDx.
Clinical Catch-Up: January 3-7
1/10/2022The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.
DEINOVE announces a favorable opinion from the DSMB for the continuation of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections
DEINOVE (Euronext Growth Paris, ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announced today that the independent Data Safety Monitoring Board (DSMB) has completed its review of the safety data from the first part of the Phase II clinical trial of DNV3837 in the treatment of Clostridioides difficile infection (CDI).
Clinical Catch-Up: July 13-17
7/20/2020It was a surprisingly big week for clinical trial updates related to COVID-19, although there was plenty of non-COVID-19 news as well. Here’s a look.
BioSpace Movers & Shakers, May 8
5/8/2020Pharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Clinical Catch-Up: January 27-31
2/3/2020It was another busy week for clinical trial updates. Here’s a look.
BioSpace Global Roundup, Dec. 12
12/12/2019Companies from across the globe provide updates to their business and pipelines.
BioSpace Global Roundup, Sept. 26
9/26/2019Companies from across the globe share updates on their business and pipelines.
A new website to highlight DEINOVE's disruptive innovation strategy
The new DEINOVE website displays an updated presentation of DEINOVE's corporate activities and identity
DEINOVE TO COLLABORATE WITH CALIBR TO EXPLORE BROADLY THE ANTI-INFECTIOUS POTENTIALS OF ITS BACTERIAL COLLECTION
CALIBR is a division of the Scripps Research, a California non-profit corporation, dedicated to finding new treatments addressing unmet medical needs;
Deinove Strengthens Its Business Development Activity With The Arrival Of Sébastien Enault
Deinove Release: A First Innovative Antibiotic Candidate Patented
Deinove Selected To Join The Tech 40 Label
Deinove Keeps Moving Forward On Carotenoids
Deinove Takes Its Carotenoids Production Forward And Initiates A Collaboration With Canada's POS Bio-Sciences
Deinove Strengthens Its Position In The United States
Deinove Successfully Completes The First Key Milestone Of Its Deinochem Program And Receives 1 Million Euros
Deinove Teams Up With MBI, Pioneer Of Afex Technology, To Evaluate Its Process On Industrial Biomass